FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209846698> ?p ?o ?g. }

• W3209846698 abstract "Abstract Chronic lymphocytic leukemia (CLL) is associated with immunocompromise and high risk of severe COVID-19 disease and mortality. Monoclonal B-Lymphocytosis (MBL) patients also have immune impairment. We evaluated humoral and cellular immune responses in 181 patients with CLL (160) and MBL (21) to correlate failed seroconversion (<50AU/mL SARS-CoV-2 II IgG assay, antibody to spike protein, Abbott Diagnostics) following each of 2 vaccine doses with clinical and laboratory parameters. Following first and second doses, 79.2% then 45% of CLL, and 50% then 9.5% of MBL respectively remained seronegative, indicating 2 vaccine doses are crucial. There was significant association between post-dose 2 antibody level with pre-vaccination reduced IgM ( p <0.0001), IgG2 ( p <0.035), IgG3 ( p <0.046), and CLL therapy within 12 months ( p <0.001) in univariate analysis. By multivariate analysis, reduced IgM ( p <0.0002) and active therapy ( p <0.0002) retained significance. There was no significant correlation with age, gender, CLL duration, IgG, IgA or lymphocyte subsets. Anti-spike protein levels varied widely and were lower in CLL, than MBL, and both lower than normal donors. Neutralization activity showed anti-spike levels <1000AU/mL were usually negative for both an early viral clade and the contemporary Delta variant. There were 72.9% of CLL and 53.3% of MBL who failed to reach anti-spike levels >1000AU/mL. In a representative subset of 32 CLL patients, 80% had normal T-cell responses by IFNγ and IL-2 FluoroSpot assay. Failed seroconversion occurred in 36.6%% of treatment-naive patients, 52.9% treatment-naive with reduced IgM, 78.1% on therapy, and 85.7% on ibrutinib. Vaccination failure is very common in CLL, including early-stage disease. 6 Key Novel Findings Comparison CLL vs MBL vs normal - 45% of CLL and 9.5% of MBL fail to seroconvert with 2 doses of COVID-19 vaccine Neutralization assay - SARS CoV-2 IgG levels <1000 AU/mL rarely associated with neutralization activity. COVID-19-specific T-cell function by FluoroSpot IFN-g and IL-2 production IgG, A, M class and IgG subclass: correlations by univariate and multivariate analysis - IgM (OR 7.29 p<0.0001), IgG2 and IgG3 subclass univariate significance Correlation with therapy – ICT, targeted therapies, and those on Ig replacement High risk of vaccination failure for all CLL, including early-stage disease, and MBL Key Points CLL and MBL show significantly impaired anti-spike antibody, viral neutralization, with cellular immune response to COVID-19 vaccination Failure to seroconvert is associated with low IgM, IgG2, IgG3, and recent therapy; many CLL and MBL patients remain COVID-19 vulnerable" @default.
• W3209846698 created "2021-11-08" @default.
• W3209846698 creator A5007187976 @default.
• W3209846698 creator A5015889173 @default.
• W3209846698 creator A5018086400 @default.
• W3209846698 creator A5024413766 @default.
• W3209846698 creator A5034792012 @default.
• W3209846698 creator A5047202249 @default.
• W3209846698 creator A5054938965 @default.
• W3209846698 creator A5063221213 @default.
• W3209846698 creator A5074574487 @default.
• W3209846698 creator A5076280606 @default.
• W3209846698 creator A5078917644 @default.
• W3209846698 creator A5081307181 @default.
• W3209846698 creator A5083872139 @default.
• W3209846698 creator A5086077349 @default.
• W3209846698 creator A5087985272 @default.
• W3209846698 creator A5090101973 @default.
• W3209846698 creator A5090116607 @default.
• W3209846698 creator A5090954355 @default.
• W3209846698 date "2021-10-30" @default.
• W3209846698 modified "2023-09-27" @default.
• W3209846698 title "COVID-19 Vaccine Failure in Chronic Lymphocytic Leukemia and Monoclonal B-Lymphocytosis; Humoral and Cellular Immunity" @default.
• W3209846698 cites W2082439383 @default.
• W3209846698 cites W2108374688 @default.
• W3209846698 cites W2123049617 @default.
• W3209846698 cites W2150044749 @default.
• W3209846698 cites W2167442438 @default.
• W3209846698 cites W2330274082 @default.
• W3209846698 cites W2563143287 @default.
• W3209846698 cites W2584993185 @default.
• W3209846698 cites W2789973114 @default.
• W3209846698 cites W2790385276 @default.
• W3209846698 cites W2793465190 @default.
• W3209846698 cites W2810013153 @default.
• W3209846698 cites W2955661053 @default.
• W3209846698 cites W2976911527 @default.
• W3209846698 cites W3024065112 @default.
• W3209846698 cites W3039049494 @default.
• W3209846698 cites W3041007898 @default.
• W3209846698 cites W3043131535 @default.
• W3209846698 cites W3046194290 @default.
• W3209846698 cites W3081513395 @default.
• W3209846698 cites W3092136311 @default.
• W3209846698 cites W3094870207 @default.
• W3209846698 cites W3123047185 @default.
• W3209846698 cites W3129554822 @default.
• W3209846698 cites W3130373731 @default.
• W3209846698 cites W3137097875 @default.
• W3209846698 cites W3156866359 @default.
• W3209846698 cites W3164040616 @default.
• W3209846698 cites W3165224470 @default.
• W3209846698 cites W3165840851 @default.
• W3209846698 cites W3181668248 @default.
• W3209846698 cites W3182196820 @default.
• W3209846698 cites W3185307733 @default.
• W3209846698 cites W3187723563 @default.
• W3209846698 cites W3192895474 @default.
• W3209846698 cites W3199394546 @default.
• W3209846698 cites W3199510295 @default.
• W3209846698 cites W3203011710 @default.
• W3209846698 cites W3203033624 @default.
• W3209846698 cites W3204177041 @default.
• W3209846698 cites W3206655348 @default.
• W3209846698 doi "https://doi.org/10.1101/2021.10.28.21265549" @default.
• W3209846698 hasPublicationYear "2021" @default.
• W3209846698 type Work @default.
• W3209846698 sameAs 3209846698 @default.
• W3209846698 citedByCount "0" @default.
• W3209846698 crossrefType "posted-content" @default.
• W3209846698 hasAuthorship W3209846698A5007187976 @default.
• W3209846698 hasAuthorship W3209846698A5015889173 @default.
• W3209846698 hasAuthorship W3209846698A5018086400 @default.
• W3209846698 hasAuthorship W3209846698A5024413766 @default.
• W3209846698 hasAuthorship W3209846698A5034792012 @default.
• W3209846698 hasAuthorship W3209846698A5047202249 @default.
• W3209846698 hasAuthorship W3209846698A5054938965 @default.
• W3209846698 hasAuthorship W3209846698A5063221213 @default.
• W3209846698 hasAuthorship W3209846698A5074574487 @default.
• W3209846698 hasAuthorship W3209846698A5076280606 @default.
• W3209846698 hasAuthorship W3209846698A5078917644 @default.
• W3209846698 hasAuthorship W3209846698A5081307181 @default.
• W3209846698 hasAuthorship W3209846698A5083872139 @default.
• W3209846698 hasAuthorship W3209846698A5086077349 @default.
• W3209846698 hasAuthorship W3209846698A5087985272 @default.
• W3209846698 hasAuthorship W3209846698A5090101973 @default.
• W3209846698 hasAuthorship W3209846698A5090116607 @default.
• W3209846698 hasAuthorship W3209846698A5090954355 @default.
• W3209846698 hasBestOaLocation W32098466981 @default.
• W3209846698 hasConcept C159654299 @default.
• W3209846698 hasConcept C203014093 @default.
• W3209846698 hasConcept C2777761686 @default.
• W3209846698 hasConcept C2777938653 @default.
• W3209846698 hasConcept C2778461978 @default.
• W3209846698 hasConcept C2780126324 @default.
• W3209846698 hasConcept C71924100 @default.
• W3209846698 hasConcept C8891405 @default.
• W3209846698 hasConceptScore W3209846698C159654299 @default.
• W3209846698 hasConceptScore W3209846698C203014093 @default.
• W3209846698 hasConceptScore W3209846698C2777761686 @default.

• next